Phase I trial of concurrent chemoradiation with weekly nedaplatin in patients with squamous cell carcinoma of the uterine cervix

Our recommended dose for a phase II trial of concurrent chemoradiation with weekly nedaplatin is 35 mg/m2. The formula can predict unbound concentration of nedaplatin based on area under the curve within 25% error.